Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia

BACKGROUND: Prophylaxis with clotting factor replacement products is recommended by the Medical and Scientific Advisory Council of the National Hemophilia Foundation as the optimal therapy for the prevention of bleeding episodes in individuals with severe hemophilia A or B (< 1 IU per dL endogeno...

Descripción completa

Detalles Bibliográficos
Autores principales: Thorat, Teja, Neumann, Peter J., Chambers, James D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2018
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397835/
https://www.ncbi.nlm.nih.gov/pubmed/29952709
http://dx.doi.org/10.18553/jmcp.2018.24.7.632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397835/
https://www.ncbi.nlm.nih.gov/pubmed/29952709
http://dx.doi.org/10.18553/jmcp.2018.24.7.632

Ejemplares similares